CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Healthy Clinical Trial

Official title:

A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAD and MAD of CORT125281 in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03335956
• Other study ID #: CORT125281-600
• Status: Completed
• Phase: Phase 1
• Start date: September 21, 2017
• Est. completion date: June 25, 2018

Study information

• Verified date: July 2018
• Source: Corcept Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This initial Phase I study will evaluate the dose-related safety and tolerability pharmacokinetics (PK) of CORT125281, and CORT125324 (active metabolite), and pharmacodynamics (PD) after single and multiple ascending oral doses of CORT125281 in healthy subjects.

Description:

Separate single-and multiple-ascending dose (SAD and MAD) parts will be conducted. Throughout each part of the study, safety, pharmacological (PD) and PK effects will be assessed. Safety and tolerability will be assessed using adverse event (AE) monitoring, measurement of vital signs, recording 12-lead electrocardiogram (ECG), physical examination and clinical laboratory safety tests. Blood samples will be collected at intervals for assay of plasma concentration of CORT125281 and CORT125324.

The SAD part of the study is double-blind, randomized and placebo-controlled with respect to CORT125281. Two cohorts, each of 9 subjects, will receive three sequential single doses of the investigational medicinal product (IMP), either CORT125281 at the assigned dose level or placebo, in a partial within-subject crossover manner. The starting dose is CORT125281, 40 mg; the rules for determining later doses are detailed within the protocol. The PD effects of CORT125281 will be examined by testing its ability to ameliorate the pharmacological effects of a concomitantly administered dose of prednisone.

The MAD part of the study will be double-blind, randomized, placebo-controlled and parallel-group with respect to CORT125281. Up to four cohorts of 8 subjects, randomized so that 6 receive CORT125281 and 2 receive placebo, will participate in the study, so that up to four dose levels of CORT125281 are studied in total. An exploratory assessment will be made of the effect of repeated doses of CORT125281 on exposure to pioglitazone, probe substrate for CYP2C8. Each subject will be admitted on Day−1 for baseline assessments. On Day1, subjects will receive a single oral dose of pioglitazone, 15mg. From Day3 to Day16 (14 days), subjects will be dosed daily with IMP (CORT125281 at the selected dose or placebo). On Day13, subjects will receive a second dose of pioglitazone, 15 mg.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: June 25, 2018
• Est. primary completion date: May 31, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Give written informed consent

2. If male, have undergone vasectomy, with no wish to have the procedure reversed

3. If female, using appropriate precautions to avoid pregnancy, defined as of nonchildbearing potential (ie, postmenopausal or permanently sterilised) or using highly effective contraception with low user-dependency

• A woman is postmenopausal if it is more than 12 months since her last menstruation, without an alternative medical cause. A concentration of FSH in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy.

• Accepted methods of permanent sterilization methods are hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

• An IUD is the only acceptable method of highly effective contraception with low user-dependency, provided that the subject has tolerated its use for at least 3 months before the first dose of study medication and undertakes not to have it removed for 1 month after the last dose.

4. Be aged 18 to 65 years inclusive

5. Have a BMI of 19 to 30 kg/m2, inclusive

6. Be willing to comply with study restrictions as described in Section 4.6

7. Be able to comply with the requirements of the entire study

8. Be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory findings

9. For multiple dose cohorts, have a morning serum cortisol within the local reference range at screening and/or Day -1

10. Have suitable veins for multiple venepunctures/cannulation

11. Be able to swallow size 0 capsules whole

Exclusion Criteria:

1. Be an employee or immediate family member of the CRU or Corcept

2. Have been previously enrolled in this study

3. Have multiple drug allergies, or be allergic to any of the components of study medication, its matching placebo, challenge agents or probe substrates (see Section 5.1)

4. Have a condition that could be aggravated by glucocorticoid blockade (eg, asthma, any chronic inflammatory condition) or activation (eg, immunodeficiency, active infection) Subjects with inactive seasonal hay fever may be included. Subjects with childhood (aged less than 18 years) asthma may be included provided they have had no symptoms and required no treatment for at least 5 years

5. In the 6 calendar months before study drug administration, on average

• Have smoked more than 5 cigarettes/day

• Have consumed more than 14 units (female) or 21 units (male) of alcohol/week

• Consumed liquorice or other glycyrrhetic acid derivatives regularly, in the judgement of the Investigator

6. In the 3 calendar months before study drug administration

• Have donated blood or plasma in excess of 400 mL

• Have participated in another clinical trial of a new chemical entity or a prescription medicine

7. Have a positive test for alcohol, smoking or drugs of abuse at screening or admission to any of the dosing sessions

8. Have clinically-relevant abnormal findings on vital signs, physical examination, laboratory screening tests, or 12-lead ECG, at screen and/or before first dose, including but not limited to:

• Abnormal ECG waveform morphology that would preclude accurate measurement of the QT interval

• QTcF >450 ms (from mean of 3 supine ECGs, performed at least 2 minutes apart)

• Stage 2 or higher hypertension (supine/semi-recumbent systolic blood pressure [SBP] >160 mmHg; diastolic blood pressure [DBP] >100 mmHg, based on mean of duplicate values recorded at least 2 minutes apart)

• Stage 1 hypertension (supine/semi-recumbent SBP 140-160 mmHg; DBP 90-100 mmHg, based on mean of duplicate values recorded at least 2 minutes apart) associated with indication for treatment ie, evidence of end-organ damage, diabetes or a 10 year cardiovascular risk, estimated using a standard calculator eg, QRisk2 2016 >20%

• Glomerular filtration rate, estimated using the chronic kidney disease epidemiology (collaboration) (CKD-EPI) method (eGFR; see Section 6.2.5) <60 mL/minute/1.73 m2

• Hypokalaemia (potassium below lower limit of normal)

• ALT, AST and/or gammaglutamyl transferase (GGT) >1.5 times the upper limit of normal

• Seropositive for hepatitis B, hepatitis C or human immunodeficiency viruses.

9. Have any medical or social reasons for not participating in the study raised by their General Practitioner/primary care physician

10. Have any other condition that might increase the risk to the individual or decrease the chance of obtaining satisfactory data, as assessed by the Investigator

11. Taken any prohibited prior medication, as described in Section 4.6.3

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• CORT125281, 40mg, fasted
CORT125281 is supplied as capsules for oral dosing
• Prednisone 25mg, fasted
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
• Placebo oral capsule, fasted
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered
• Pioglitazone 15mg Tablet
Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered
• Placebo oral capsule, fed
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered
• Prednisone 25mg, fed
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
• CORT125281, 120mg, fasted
CORT125281 is supplied as capsules for oral dosing
• CORT125281, 360mg, fasted
CORT125281 is supplied as capsules for oral dosing
• CORT125281, 720mg, fasted
CORT125281 is supplied as capsules for oral dosing
• CORT125281, 360mg, fed
CORT125281 is supplied as capsules for oral dosing
• CORT125281, 360mg
CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
• CORT125281, 120mg
CORT125281 is supplied as capsules for oral dosing once daily
• CORT125281, 180mg
CORT125281 is supplied as capsules for oral dosing twice daily
• CORT125281, 240mg
CORT125281 is supplied as capsules for oral dosing twice daily
• CORT125281, 360mg
CORT125281 is supplied as capsules for oral dosing once daily
• Placebo oral capsule
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal
• Placebo oral capsule
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, twice daily
• Placebo oral capsule
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, once daily

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research	London

Sponsors (1)

Lead Sponsor	Collaborator
Corcept Therapeutics

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events (AEs)		SAD Cohorts Day 1 to Day 14; MAD Cohorts Day 1 to Day 30
Secondary	AUCtau Pharmacokinetic (PK) parameter	Area under the curve over a dose-interval (AUCtau)	MAD Cohorts Day 3 to 19
Secondary	AUC 0-tz PK parameter	Area under the curve from the time of dosing until the last quantifiable concentration (AUC 0-tz)	CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
Secondary	AUC 0-infinity PK parameter	Area under the curve from the time of dosing extrapolated to infinity (AUC 0-infinity)	CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
Secondary	Cmax PK parameter	Maximum concentration (Cmax)	CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
Secondary	Cmin PK parameter	Minimum concentration within a dose interval (Cmin)	MAD Cohorts Day 3 to 19
Secondary	Tmax PK parameter	Time to maximum concentration (Tmax)	SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	tlag PK parameter	Latest time after dosing before the first quantifiable concentration (tlag)	SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	apparent terminal rate constant PK parameter		SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	t1/2 PK parameter	Apparent terminal elimination half-life (t1/2)	SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	MRT PK parameter	Mean residence time (MRT)	SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	Vz/F PK parameter	Apparent oral volume of distribution during the terminal elimination phase (Vz/F)	SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	CL/F PK parameter	Apparent oral clearance (CL/F)	SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
Secondary	Observed accumulation ratio PK parameter		MAD Cohorts Day 3 to 19
Secondary	4ß-OH cholesterol PK parameter	4ß-Hydroxycholesterol (4ß-OH)	MAD Cohorts Day 1 to Day 17
Secondary	Pharmacodynamics (PD) Peripheral blood neutrophil, eosinophil and lymphocyte counts		SAD Cohorts pre-dose through 24 hours post dose
Secondary	PD Serum osteocalcin		SAD Cohorts pre-dose through 24 hours post dose
Secondary	PD Pre- and postprandial blood glucose		SAD Cohorts Day 1, pre-dose to 6 hours post dose
Secondary	PD Cytokines		SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10
Secondary	PD T cell profiling by flow cytometry		SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10
Secondary	PD Gene expression for glucocorticoid-modulated genes		SAD Cohorts Day 1, pre-dose to 4 hours post dose
Secondary	PD Cortisol		MAD Cohorts pre-dose to Day 16
Secondary	PD ACTH	Adrenocorticotropic hormone (ACTH)	MAD Cohorts pre-dose to Day 16
Secondary	PD DHEA S	Dehydroepiandrosterone sulphate (DHEA-S)	MAD Cohorts Day 3 to Day 16
Secondary	PD androstenedione		MAD Cohorts Day 3 to Day 16
Secondary	PD Fasting glucose		MAD Cohorts Day 1 to Day 13
Secondary	PD insulin		MAD Cohorts Day 1 to Day 13
Secondary	PD HOMA-IR	Homeostatic model assessment of insulin-resistance (HOMA-IR)	MAD Cohorts Day 1 to Day 13